Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Intellia Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Intellia Therapeutics, Inc.

NTLA

Intellia Therapeutics, Inc.

About Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading clinical-stage biotech company specializing in CRISPR-based gene editing therapies. Its core focus is developing in vivo and ex vivo treatments for genetic diseases, including rare disorders like ATTR amyloidosis and hereditary angioedema, as well as cancer and autoimmune conditions. The company leverages proprietary technologies, strategic collaborations, and a broad IP portfolio to deliver potentially curative, precision medicines.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Intellia Therapeutics, Inc.

1
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports Q1 2026 Financial Results with Revenue Decline and Reduced Operating Expenses

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports $412.7M Net Loss, Collaboration Revenue Increases

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports Q3 2025 Financial Results with Increased Collaboration Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports Q2 2025 Financial Results with Improved Net Loss and Revenue Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports $114.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports $519M Net Loss and Increased Collaboration Revenue for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Intellia Therapeutics, Inc. Intellia Therapeutics Reports Financial Challenges, Decrease in Cash Reserves, and Increased Research and Development Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments